Literature DB >> 6783532

Polyvalent antisera to Pseudomonas ribosomal vaccines: protection of mice against clinically isolated strains.

M M Lieberman, G L Wright, K M Wolcott, D C McKissock-Desoto.   

Abstract

The preparation of polyvalent antisera to ribosomal vaccines from Pseudomonas aeruginosa is described. The ability of these antisera to protect mice by passive immunization against challenge with randomly chosen, clinically isolated strains of P. aeruginosa is reported. Significant protection was achieved against 34 of 40 strains tested (85%). Included among these strains against which protection was achieved were four mucoid strains. In addition, the degree of cross-protection attainable by the ribosomal vaccines was investigated. The results obtained indicated that these vaccines are generally serotype specific.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6783532      PMCID: PMC551144          DOI: 10.1128/iai.29.2.489-493.1980

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

1.  Development of immunotherapy for infections due to Pseudomonas aeruginosa.

Authors:  M W Fisher
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

2.  Immunization against Pseudomonas in infection after thermal injury.

Authors:  J Wesley; A Fisher; M W Fisher
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

3.  Immunization against Pseudomonas aeruginosa. II. Purification and characterization of the protective factor from the alcohol-precipitated fraction.

Authors:  T H Alms; J A Bass
Journal:  J Infect Dis       Date:  1967-06       Impact factor: 5.226

4.  Isolation and characterization of antigenic components of a new heptavalent Pseudomonas vaccine.

Authors:  S Hanessian; W Regan; D Watson; T H Haskell
Journal:  Nat New Biol       Date:  1971-02-17

5.  Exotoxins of Pseudomonas aeruginosa. II. Concentration, purification, and characterization of exotoxin A.

Authors:  P V Liu; S Yoshii; H Hsieh
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

6.  Pseudomonas aeruginosa infection in cystic fibrosis. Distribution of B and T lymphocytes in relation to the humoral immune response.

Authors:  N Hoiby; L Mathiesen
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1974-08

7.  Pseudomonas aeruginosa infection in cystic fibrosis. Relationship between mucoid strains of Pseudomonas aeruginosa and the humoral immune response.

Authors:  N Hoiby
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1974-08

8.  Common protective antigen (OEP) of Pseudomonas aeruginosa.

Authors:  C Abe; H Shionoya; Y Hirao; K Okada; J Y Homma
Journal:  Jpn J Exp Med       Date:  1975-10

9.  A new polyvalent Pseudomonas vaccine.

Authors:  J M Miler; J F Spilsbury; R J Jones; E A Roe; E J Lowbury
Journal:  J Med Microbiol       Date:  1977-02       Impact factor: 2.472

10.  Pseudomonas aeruginosa: immune status in patients with cystic fibrosis.

Authors:  R G Doggett; G M Harrison
Journal:  Infect Immun       Date:  1972-10       Impact factor: 3.441

View more
  1 in total

1.  Kinetic analysis of microbe opsonification based on stimulated polymorphonuclear leukocyte oxygenation activity.

Authors:  R C Allen; M M Lieberman
Journal:  Infect Immun       Date:  1984-08       Impact factor: 3.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.